Stijn Rogé

Stijn Rogé

Auto-generated profile, based on publicly available information

Stijn Rogé

Department of Biomedical Sciences, Unit of Parasite Diagnostics, Institute of Tropical Medicine, Nationalestraat 155, B-2000 Antwerp, Belgium; Laboratory for Molecular Plant Physiology and Biotechnology, Department of Biology, University of Antwerp, Groenenborgerlaan 171, B-2020 Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Veterinary Parasitology
Verified
Journal Article
Closed access
SRS. Rogé
S. Rogé
NRN. Van Reet
N. Van Reet
SOS. Odiwuor
S. Odiwuor
TTT. Tran
T. Tran
KSK. Schildermans
K. Schildermans
PBP. Büscher
P. Büscher

17 July 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SRStijn Rogé
Stijn Rogé
LNLiesbeth Van Nieuwenhove
Liesbeth Van Nieuwenhove
MMMagali Meul
Magali Meul
AHAnnick Heykers
Annick Heykers
AKAnnette Brouwer de Koning
Annette Brouwer de Koning
PBPhilippe Büscher
Philippe Büscher
Screening tests for gambiense sleeping sickness, such as the CATT/T. b. gambiense and a recently developed lateral flow tests, are hitherto based on native variant surface glycoproteins (VSGs), namely LiTat 1.3 and LiTat 1.5, purified from highly virulent trypanosome strains grown in rodents. We have expressed SUMO (small ubiquitin-like modifier) fusion proteins of the immunogenic N-terminal part of these antigens in the yeast Pichia pastoris. The secreted recombinant proteins were affinity purified with yields up to 10 mg per liter cell culture. The diagnostic potential of each separate antigen and a mixture of both antigens was confirmed in ELISA on sera from 88 HAT patients and 74 endemic non-HAT controls. Replacement of native antigens in the screening tests for sleeping sickness by recombinant proteins will eliminate both the infection risk for the laboratory staff during antigen production and the need for laboratory animals. Upscaling production of recombinant antigens, e.g. in biofermentors, is straightforward thus leading to improved standardisation of antigen production and reduced production costs, which on their turn will increase the availability and affordability of the diagnostic tests needed for the elimination of gambiense HAT. Population screening for the chronic form of sleeping sickness or gambiense human African trypanosomiasis (HAT) is still based on an antibody detection test against the native variant surface glycoprotein (VSG) LiTat 1.3. This protein is produced through massive infections of lab animals with highly virulent parasites. We aim to replace this native antigen with recombinant VSGs, both LiTat 1.3 and LiTat 1.5, expressed in the yeast Pichia pastoris. The diagnostic potential of these recombinants was confirmed in ELISA with sera from HAT patients and negative controls. Replacement of the native LiTat 1.3 VSG with these recombinants would prevent the infection and sacrifice of lab animals and the inherent infection risk linked to the production of the screening test. Upscaling production of recombinant antigens, e.g. in biofermentors, is straightforward thus leading to improved standardisation of antigen production and reduced production costs, which on their turn will increase the availability and affordability of the diagnostic tests needed for the elimination of gambiense HAT.

15 July 2013 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
NRNick Van Reet
Nick Van Reet
PPPati Patient Pyana
Pati Patient Pyana
SRStijn Rogé
Stijn Rogé
FCFilip Claes
Filip Claes
PBPhilippe Büscher
Philippe Büscher
New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handling this subspecies and the lack of an efficient viability assay to monitor drug efficacy.

1 October 2014 in Veterinary Parasitology
Verified
Journal Article
Closed access
SRS. Rogé
S. Rogé
RBR. Baelmans
R. Baelmans
FCF. Claes
F. Claes
VLV. Lejon
V. Lejon
YGY. Guisez
Y. Guisez
PBP. Büscher
P. Büscher